Aprogen Biologics lends KRW 29.1 billion to Ainsfac at 4.6% interest

Bitget2026/09/23 07:27

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aprogen Biologics’ board on Sept. 23 resolved to extend a cash loan to Ainsfac.
Loan set at KRW 29.1 billion, equal to 10.5% of equity based on year-end 2025 consolidated statements.
Facility priced at 4.6%, scheduled to run from Sept. 28, 2026 to Sept. 27, 2027.
Funding earmarked for strategic cash management to improve financial structure, with collateral to include Ainsfac investment interests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Biologics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923800503), on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aprogen Biologics lends KRW 29.1 billion to Ainsfac at 4.6% interest

You may also like

Crypto prices